2022-503071-28-00已完成3 期
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 106
- 试验地点
- 21
- 主要终点
- Overall survival (OS)
研究概览
简要总结
To evaluate the efficacy of zimberelimab and domvanalimab combination therapy compared to pembrolizumab in OS (Arm D vs Arm E)
研究设计
- 分配方式
- Randomized
- 主要目的
- Study Part 2
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Histologically confirmed, treatment naïve, locally advanced or metastatic (stage IIIB IV per AJCC version 8), squamous or non-squamous NSCLC with documented high PD L1 expression (TC ≥ 50%) as determined by the VENTANA SP263 IHC assay, as assessed by central laboratories).
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- •Must have at least 1 measurable lesion per RECIST v1.1
- •Adequate organ and marrow function
- •If a participant has brain or meningeal metastases, the participant must meet the following criteria: a. Have no evidence of progression by neurologic symptoms or signs for at least 4 weeks prior to the first dose, b) Participants with previously treated brain metastases may participate provided they have stable central nervous system (CNS) disease for at least 4 weeks prior to enrollment, c) Stable CNS disease is defined as resolution of all neurologic symptoms to baseline, having no evidence of new or enlarging brain metastases, and not requiring use of corticosteroids for CNS disease for at least 14 days prior to the start of study treatment. Participants who have had brain metastases resected or have received whole brain radiotherapy ending at least 4 weeks (or stereotactic radiotherapy ending at least 2 weeks) prior to initiation of study treatment are permitted d) Carcinomatous meningitis is excluded regardless of clinical stability
排除标准
- •Presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved by local health authority and available
- •Use of any live vaccines against infectious diseases within 28 days of first dose
- •Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy.
- •Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
- •Prior treatment with any anti-PD-1, anti-PD-L1 or any other antibody targeting an immune checkpoint
结局指标
主要结局
Overall survival (OS)
Overall survival (OS)
次要结局
- PFS according to RECIST v1.1 by blinded independent central review, and confirmed ORR according to RECIST v1.1 as assessed by BICR.
- Presence of treatment-emergent adverse events, and Changes in vital signs measurements and clinical laboratory parameters
- Time to first symptom deterioration in NSCLC-SAQ total score
研究者
Medical Director
Scientific
Arcus Biosciences Inc.
研究点 (21)
Loading locations...
相似试验
招募中
2 期
N/A2024-513121-22-00Gilead Sciences Inc.21
进行中（未招募）
1 期
Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Non-Small Cell Lung CancerEUCTR2020-003562-39-SKArcus Biosciences, Inc.600
招募中
1 期
Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung CancerSquamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2022-503071-28-00Arcus Biosciences Inc.792
进行中（未招募）
1 期
Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung CancerEUCTR2020-003562-39-GRArcus Biosciences, Inc.600
进行中（未招募）
1 期
Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Lung CancerEUCTR2020-003562-39-IEArcus Biosciences, Inc.600